

# PCL Department Publications - 2000

## "A,B"

Thavendiranathan P, Mendonca A, Iracleous C, Likhodii S, Dell C, Cunnane S, **Burnham WM**: The MCT ketogenic diet: effects on animal seizure models. *Exp Neurol*. 161: 696-703 (2000).

Frantseva MV, Perez Velazques JL, Tsoraklidis G, Mendonca AJ, Adamchik Y, Mills LR, Carlen PL, **Burnham WM**: Oxidative stress is involved in seizure-induced neurodegeneration in the kindling model of epilepsy. *Neuroscience*. 97: 431-435 (2000).

Snead OC, Banerjee PK, **Burnham WM**, Hampson D: Modulation of absence seizures by the GABAA receptor: a critical role for mGluR4. *J Neurosci*. 20: 6218-6224 (2000).

Scott BW, Wojtowicz JM, **Burnham WM**: Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. *Exp Neurol*. 165: 231-236 (2000).

Edwards HE, MacLusky NJ, **Burnham WM**: The effect of seizures and kindling on reproductive hormones in the rat. *Neurosci Biobehav Rev*. 24: 753-762 (2000).

Francis J, Eubanks JH, **Burnham WM**: Diazepam-potentiated [3H] phenytoin binding is associated with peripheral-type benzodiazepine receptors and not with voltage-dependent sodium channels. *Brain Res*. 876: 131-140 (2000).

Likhodii SS, Musa K, Mendonca A, Dell C, **Burnham WM**, Cunnane SC: Dietary fat, ketosis and seizure protection in rats on the ketogenic diet. *Epilepsia* 41: 1400-1410 (2000).

---

## "C, D"

**DaSilva JN**, Burrow TE, Wilson AA, Houle S: Synthesis of R-[N-methyl-13C]SKF 82957 from [13C]methyl iodide and [13C]methyl triflate. *J Labelled Cpd Radiopharm*. 43: 701-710 (2000).

Houle S, **DaSilva JN**, Wilson AA: Imaging 5-HT1A receptors with PET: WAY-100635 and analogues. *Nucl Med Biol*. 27: 463-466 (2000).

---

**Dorian P**, Newman D: Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: *Europace* 2: 277-85 (2000).

Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C, **Dorian P**: Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. *Amer J Cardiology* 86: 764-8 (2000).

**Dorian P**, Jung W, Newman D, Paquette M, Wood K, Ayers GM, Camm J, Akhtar M, Luderitz B: The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. *J Amer College of Cardiology* 36: 1303-9 (2000).

**Dorian P**: Combination ICD and drug treatments-best options. *Resuscitation* 45: S3-6 (2000).

Connolly SJ, Gent M, Roberts RS, **Dorian P**, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ., O'Brien B: Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 101: 1297-302 (2000).

Jeejeebhoy FM, **Dorian P**, Newman DM: Panic disorder and the heart: a cardiology perspective. *J Psychosomatic Res.* 48: 393-403 (2000).

**Dorian P**, Philippon F: The management of acute ventricular tachycardia or fibrillation. *Can J Cardiol.* 16 Suppl C:16C-9C (2000).

Nanthakumar K, Paquette M, Newman D, Deno DC, Malden L, Gunderson B, Gilkerson J, Greene M, Heng D, **Dorian P**: Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. *Amer Heart J.* 139: 797-803 (2000).

Nanthakumar K, **Dorian P**, Paquette M, Hutchison S, Andrews J, Newman D: Effect of physiological mechanical perturbations on intact human myocardial repolarization. *Cardiovascular Res.* 45: 303-9 (2000).

Roy D, Talajic M, **Dorian P**, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B: Amiodarone to prevent recurrence of atrial fibrillation. *Canadian Trial of Atrial Fibrillation Investigators. New Engl J Med.* 342: 913-20 (2000).

---

## "E, F"

Ring A, Tothfalusi L, **Endrenyi L**, Weiss M: Sensitivity of empirical metrics of rate of absorption in bioequivalence studies. *Pharm Res.* 17: 583-588 (2000).

Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, **Endrenyi L**, Kashura ADM: Evaluation of the genetic component of variability in CYP3A4 activity. *Pharmacogenetics* 10: 373-388 (2000).

**Endrenyi L**, Taback N, Tothfalusi L: Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence. *Stat Med* 19: 2867-2878 (2000).

---

## "G"

Lee D, **George SR**, Fan T, Cheng R, Nguyen T, O'Dowd BF: The novel neuropeptide apelin has a distinct distribution in brain and periphery. *J Neurochemistry* 74: 34-41 (2000).

O'Dowd BF, Lee DK, Huang W, Nguyen T, Cheng R, Liu Y, Gershengorn MC, **George SR**: TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared to TRH-R1. *Mol Endocrinology* 14: 183-193 (2000).

Vandenbergh J, Thompson M, Comings D, Sellers E, Tyndale R, **George SR**, O'Dowd BF, Uhl G: Mutation analysis of the dopamine transporter (DAT1) gene: Three novel polymorphisms show no association with Tourette's syndrome or alcohol dependence. *Mol Psychiatry* 5: 283-292 (2000).

Karasinska J, **George SR**, El-Ghundi M, Fletcher P, O'Dowd BF: Modification of the D1 receptor knockout phenotype in mice lacking both D1 and D3 dopamine receptors. *Eur J Pharmacol.* 399: 171-181 (2000).

Thompson M, Gonzalez N, Nguyen T, Comings DE, **George SR**, O'Dowd BF: Serotonin transporter gene polymorphisms in alcohol dependence. *Alcohol* 22: 61-67 (2000).

Lee SP, O'Dowd BF, Xie Z, Varghese G, **George SR**: Oligomerization of dopamine and serotonin receptors. *Neuropsychopharmacology* 23: S32-S40 (2000).

Tong Y, Chabot J, Shen S, O'Dowd BF, **George SR**, Quirion R: Ontogenic profile of the expression of the mu opioid receptor gene in the rat telencephalon and diencephalon: an in situ hybridization study. *J Chem Neuroanatomy* 18: 209-222 (2000).

Lee DK, Lynch KR, Nguyen T, Im D, Cheng R, Saldivia VR, Liu Y, Liu IS, Heng HH, Seeman P, **George SR**, O'Dowd BF, Marchese A: Cloning and characterization of additional members of the G protein-coupled receptor family. *Biochim Biophys Acta* 1490: 311-323 (2000).

Deng HB, Yu Y, Pak Y, O'Dowd BF, **George SR**, Surratt CK, Uhl GR, Wang JB: The role of the C-terminus in agonist-induced mu opioid receptor phosphorylation and desensitization. *Biochemistry* 39: 5492-5499 (2000).

Im DS, Heise CE, Harding MA, **George SR**, O'Dowd BF, Theodorescu D, Lynch KR: Molecular cloning and characterization of a novel lysophosphatidic acid receptor, Edg-7, expressed in prostate. *Mol Pharmacology* 57: 753-759 (2000).

Lee SP, O'Dowd BF, Ng GYK, Varghese G, Nguyen T, **George SR**: D2 dopamine receptors are antagonized by truncated receptor fragments and exist only as oligomers in the cell. *Mol Pharmacology* 58: 120-128 (2000).

Im DS, Heise CE, Ancellin N, O'Dowd BF, Shei G, Heavens RP, Rigby MR, Hla T, Mandala S, McAllister G, **George SR**, Lynch KR: Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. *J Biol Chem.* 275: 14281-14286 (2000).

**George SR**, Fan T, Xie Z, Tse R, Tam V, Varghese G, O'Dowd BF: Hetero-oligomerization of m and d opioid receptors: Generation of a novel pharmacology. *J Biol Chem.* 275: 26128-26135 (2000).

Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocca R, Bellefeuille JN, Abramowitz M, Cheng R, Williams DL, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, **George SR**, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 (CysLT2) receptor. *J Biol Chem.* 275: 30531-30536 (2000).

Elmhurst JL, O'Dowd BF, Ng GYK, **George SR**: The alternatively spliced variant D3nf decreases the capacity of the D3 dopamine receptor to bind ligand. *Mol Br Res.* 80: 63-74 (2000).

Liu ISC, **George SR**, Seeman P: The human dopamine D2longer receptor has a high-affinity state and inhibits adenylyl cyclase. *Mol Brain Res.* 77: 281-284 (2000).

O'Dowd, B.F., Lee, D.K., Huang, W., Nguyen, T., Cheng, R., Liu, Y., Gershengorn, M.C. and **George, S.R.** TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared to TRH-R1. *Molecular Endocrinology* 14:183-193 (2000).

.

---

Salmena LJ, Lam V, McPherson JP, **Goldenberg GJ**: Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase II expression. *Biochem Pharmacol.* 61: 795-802 (2001).

---

Hein DW, McQueen CA, **Grant DM**, Goodfellow GH, Kadlubar FF, Weber WW: Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. *Drug Metab Dispos.* 28: 1425-32 (2000).

**Grant DM**, Goodfellow GH, Sugamori K, Durette K: Pharmacogenetics of the human arylamine N-acetyltransferases. *Pharmacology* 61: 204-11 (2000).

Hein DW, **Grant DM**, Sim E: Update on consensus arylamine N-acetyltransferase gene nomenclature. *Pharmacogenetics* 10: 291-2 (2000).

Pfost DR, Boyce-Jacino MT, **Grant DM**: A SNPshot: pharmacogenetics and the future of drug therapy. *Trends in Biotechnology* 18: 334-8 (2000).

Goodfellow GH, Dupret JM, **Grant DM**: Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. *Biochem J.* 348: 159-66 (2000).

Windmill KF, Gaedigk A, Hall PM, Samaratunga H, **Grant DM**, McManus ME: Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. *Toxicol Sci* 54: 19-29 (2000).

---

Margolin A, Avants K, Setaro JF, Rinder HM, **Grupp LA**: Cocaine, HIV and their cardiovascular effects: Is there a role for ACE-inhibitor therapy. *Drug Alcohol Dependence* 61: 35-45 (2000).

---

## "H"

**Haas DA**, Pynn B, Sands T: Drug use for the pregnant or lactating patient. *General Dentistry*, 48: 54-60 (2000).

Foong WC, **Haas DA**: Drugs in Dentistry. *Compendium of Pharmaceuticals and Specialties*, 35th ed. L28-30 (2000).

---

Huang XP, **Hampson DR**: Inhibition of microtubule formation by metabotropic glutamate receptors. *J Neurochem* 74: 104-113 (2000).

Benitez R, Fernandez-Capetillo O, Lazaro E, Mateos JM, Osorio A, Elezgarai I, Bilbao A, Lingenhoeh K, Van der Putten H, **Hampson DR**, Kuhn R, Knopfel T, Grandes P: Immunocytochemical localization of the metabotropic glutamate receptor mGluR4a in the piriform cortex of the rat. *J Comparative Neurology* 417: 263-274 (2000).

Peltekova V, Han G, Soleymanlou N, **Hampson DR**: Constraints on proper folding of the amino terminal domain of group III metabotropic glutamate receptors. *Mol Br Res.* 76: 180-190 (2000).

Snead OC, Banerjee PK, Burnham M, **Hampson DR**: Modulation of absence seizures by the GABAA receptor: A critical role for mGluR4. *J Neurosci* 20: 6218-6224 (2000).

Bruno V, Ksiazek I, Battaglia G, Van der Putten H, Lukic S, Leonhardt T, Inderbitzin W, Gasparini F, Kuhn R, **Hampson DR**, Nicoletti F, Flor PJ: Neuroprotective activity of group III metabotropic glutamate receptor agonists in cultured cortical neurons is mediated by the mGluR4 subtype. *J Neurosci.* 20: 6413-6420 (2000).

---

## "I, J"

Mae T, **Inaba T**, Konishi E, Hosoe K, Hidaka T: Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. *Xenobiotica* 30: 565-574 (2000).

---

Lee A, Moretti M, Collanties A, Chong D, Mazzotta P, Koren G, Marchant SS, **Ito S**: Choice of breastfeeding and physician's advice: a cohort study of women receiving propylthiouracil. *Pediatrics* 106: 27-30 (2000).

**Ito S**: Maternal drug therapy and breast-feeding. *New Engl J Med.* 343: 118-126 (2000).

Bar-Oz B, Nulman I, Koren G, **Ito S**: Anticonvulsants and breastfeeding. *Paediatr Drugs* 2:113-126 (2000).

Lala P, **Ito S**, Lingwood C: Retroviral transfection of MDCK cells with human MDR1 results in a major increase in globotriaosyl ceramide and 105 -106 fold increased cell sensitivity to verocytotoxin: role of P-glycoprotein in glycolipid synthesis. *J Biol Chem.* 275: 6246-6251 (2000).

Tunzi C, Harper PA, Bar-Oz B, Valore E, Semple JL, Watson-MacDonell J, Ganz T, **Ito S**: b-defensin expression in human mammary gland epithelia. *Ped Res.* 48: 30-35 (2000).

Cowan KN, Heilbut A, Humpl T, Lam C, **Ito S**, Rabinovitch M: Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. *Nature Medicine* 6 :698-702 (2000).

Woodland C, Blowey D, **Ito S**, Canille G, Wainer I, Klein J, Koren G: Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. *Life Sci.* 68: 109-17 (2000).

---

## "K"

**Kalant H**: Effects of food and body composition on blood alcohol curves. *Alcoholism: Clin Exp Res.* 24: 413-414 (2000).

**Kalant H**: Classic Texts Revisited: Terry and Pellens "The Opium Problem" (1928). *Addiction* 95: 1585-1587 (2000).

**Kalant H:** Nicotine as an addictive substance. In: Ferrence R, Slade J, Room R, Pope M, (eds.). Nicotine and Public Health. Washington, DC: Am Publ Health Assoc. pp. 117-134 (2000),

---

**Kalow W:** Pharmacogenetics and Evolution. (Editorial) Pharmacogenetics 10: 1-3 (2000).

Basile VS, Özdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, **Kalow W**, Macciardi FM, Kennedy JL: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5: 410-417 (2000).

Özdemir V, **Kalow W**, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba ADM: Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 10: 373-388 (2000).

---

Worsley JN, Moszczynska A, Falardeau P, Kalasinsky KS, Schmunk G, Guttman M, Furukawa Y, Ang L, Adams V, Reiber G, Anthony RA, Wickham D, **Kish SJ:** Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Molecular Psychiatry 5: 664-72 (2000).

Kalasinsky KS, Bosy TZ, Schmunk GA, Ang L, Adams V, Gore SB, Smialek J, Furukawa Y, Guttman M, **Kish SJ:** Regional distribution of cocaine in postmortem brain of chronic human cocaine users. J Forensic Sci. 45: 1041-8 (2000).

**Kish SJ,** Furukawa Y, Ang L, Vorce SP, Kalasinsky KS: Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 55: 294-6 (2000).

Furukawa Y, **Kish SJ,** Lang AE: Scoliosis in a dopa-responsive dystonia family with a mutation of the GTP cyclohydrolase I gene. Neurology 54: 2187 (2000).

Furukawa Y, Hornykiewicz O, Fahn S, **Kish SJ:** Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology 54: 1193-5 (2000).

Ross BM, Eder K, Moszczynska A, Mamalias N, Lamarche J, Ang L, Pandolfo M, Rouleau G, Kirchgessner M, **Kish SJ:** Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich's ataxia and spinocerebellar atrophy type-1. Movement Disorders 15: 294-300 (2000).

McLeman ER, Warsh JJ, Ang L, Li PP, Kalasinsky KS, Ross BM, Tong J, Schmunk G, Adams V, **Kish SJ:** The human nucleus accumbens is highly susceptible to G protein down-regulation by methamphetamine and heroin. J Neurochem. 74: 2120-6 (2000).



Furukawa Y, Guttman M, Sparagana SP, Trugman JM, Hyland K, Wyatt P, Lang AE, Rouleau GA, Shimadzu M, **Kish SJ**: Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. *Annals of Neurology* 47: 517-20 (2000).

---

Challis D, Pfaner CD, Ritchie K, **Koren G**, Tesoro A: Glucose metabolism was elevated and vascular resistance and materno-fetal transfer normal in perfused placental cotyleons from severely growth restricted human fetuses. *Ped Res.* 47: 309-15 (2000).

van Dadelszen P, Ornstein MP, Logan AG, **Koren G**, Magee L: Reduction in mean arterial pressure in women with mild-to-moderate pregnancy hypertension is associated with fetal growth restriction. A meta-regression of the randomized controlled trials. *Lancet* 355: 87-92 (2000).

Dallas S, Read SE, King S, **Koren G**, Bendayan R: Pharmacokinetic interaction between zidovune and TMP-SMX in HIV-1 infected children. *Can J Inf Dis.* 11: 254-258 (2000).

Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, **Koren G**: Prospective, controlled, multicentre study of loperamide in pregnancy. *Can J Gastroenterol.* 14: 185-187 (2000).

Theis JG, Chan HS, Greenberg ML, Malkin D, Karaskov V, Moncica I, **Koren G**, Doyle J: Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. *Med Pediatr Oncol.* 34: 242-9 (2000).

Addis A, **Koren G**: Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. *Psychol Med.* 30: 89-94 (2000).

Berkovitch M, Livne A, Lushkov G, Segal M, Talmor C, Bentur Y, Klein J, **Koren G**: The efficacy of oral deferiprone in acute iron poisoning. *Am J Emerg Med.* 18: 36-40 (2000).

Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, **Koren G**: Prospective, controlled, multicentre study of loperamide in pregnancy. *Can J Gastroenterol.* 14: 185-7 (2000).

Pole M, Einarson A, Pairaudeau N, Einarson T, **Koren G**: Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. *J Clin Pharmacol.* 294: 141-6 (2000).

Pastrakuljic A, Derewlany LO, Knie B, **Koren G**: The effects of cocaine and nicotine on amino acid transport across the human placental cotyledon perfused in vitro. *J Pharmacol Exp Ther.* 294: 141-6 (2000).

Lee A, Moretti ME, Collantes A, Chung D, Mazzotta P, **Koren G**, Merchant SS, Ito S: Choice of breastfeeding and physicians' advice: a cohort study of women receiving propylthiouracil. *Pediatrics* 106: 27-30 (2000).



**Koren G:** Intranasal midazolam for febrile seizures. A step forward in treating a common and distressing condition. *BMJ* 321: 64-5 (2000).

Einarson A, Parshuram C, **Koren G:** Periconceptional use of folic acid to reduce the rates of neural tube defects: is it working? *Reprod Toxicol.* 14: 291-2 (2000).

Kapur BM, Selby P, Latowsky M, Singh M, **Koren G:** CEDIA's EDDP immunoassay is a cost-effective compliance marker in an opiate dependency program. *Clin Biochem.* 33: 230 (2000).

Bar-Oz B, Nulman I, **Koren G,** Ito S: Anticonvulsants and breastfeeding: a critical review. *Paediatr Drugs* 2: 113-26 (2000),

Diav-Citrin O, Rathnapalan S, Grouhi M, Roifman C, **Koren G:** Medication errors in paediatrics: a case report and systematic review of risk factors. *Paediatr Drugs* 2: 239-42 (2000).

Kopecky EA, Ryan ML, Barrett JT, Seaward PG, Ryan G, **Koren G,** Amankwah K: Fetal response to maternally administered morphine. *Am J Obstet Gynecol.* 183: 424-430 (2000).

Mazzotta P, Maltepe C, Navioz Y, Magee LA, **Koren G:** Attitudes, management and consequences of nausea and vomiting of pregnancy in the United States and Canada. *Int J Gynaecol Obstet.* 70: 359-65 (2000)

Bar-Oz B, Moretti ME, Bishai R, Mareels G, Van Tittelboom T, Verspeelt J, **Koren G:** Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. *Am J Obstet Gynecol.* 183: 617-20 (2000).

**Koren G:** Appraisal of drug therapy for nausea and vomiting of pregnancy: I. The place effect-methodological and practical considerations. *Can J Clin Pharmacol.* 7: 135-7 (2000). Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee LA, **Koren G:** Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6). *Can J Clin Pharmacol.* 7: 138-43 (2000).

Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, **Koren G:** A randomized prospective crossover trial of amlodipine in pediatric hypertens. *Pediatr Nephrol.* 14: 1083-7 (2000).

Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, **Koren G:** Pregnancy outcome following gestational exposure to echinacea: A prospective controlled study. *Arch Intern Med.* 160: 3141-3 (2000).

Mazzotta P, Stewart D, Atanackovic G, **Koren G,** Magee LA: Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic therapy. *J Psychosom Obstet Gynaecol.* 21: 129-36 (2000).

Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, **Koren**

**G:** Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 62: 385-92 (2000).

Taddio A, **Koren G:** The pediatric forum: pain indication in circumcision. *Arch Pediatr Adolesc Med.* 154: 1275 (2000).

Lee J, Einarson A, Gallo M, Okotore B, **Koren G:** Longitudinal change in the treatment of nausea and vomiting of pregnancy in Ontario. *Can J Pharmacol.* 205-8 (2000).

**Koren G:** Does breastfeeding have an effect on intelligence? *Can Fam Phys* 46: 2197-9, 2000.

Einarson A, Levichek Z, Einarson TR, **Koren G:** The antiemetic effect of cetirizine during pregnancy. *Ann Pharmacother.* 34: 1486-7 (2000).

Bar-Oz B, Ito S, Parks V, Maurer MP, **Koren G:** Estimation of neonatal exposure after accidental ingestion of lufenuron in a breastfeeding mother. *J Hum Lact.* 16: 229-30 (2000).

Kozer E, **Koren G:** The risk of spontaneous abortion was increased with high levels but not with moderate levels of caffeine consumption. *Evidenced-Based. OBGYN.* 2: 73 (2000).

Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM, Albano L, Llere JC, Almeida JC, Duarte A, Cavalcanti DP, Goloni-Bertollo E, Conte A, **Koren G,** Addis A: Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. *Am J Med Genet.* 95: 302-6 (2000).

Kozer E, Verjee Z, **Koren G:** Misdiagnosis of a mexiletine overdose because of a nonspecific result of urina toxicologic screening. *N Engl J Med.* 343: 1971-2 (2000).

Addis A, Dolovich LR, Einarson TR, **Koren G:** Can we use anxiolytics during pregnancy without anxiety? *Can Fam Physician.* 46: 549-51 (2000).

Rathnapalan S, Diav-Citrin O, King SM, **Koren G:** Universal HIV testing in pregnancy. *Op cit.* 46: 508-10, 519-22 (2000).

Addis A, Dolovich LR, Einarson TR, **Koren G:** Can we use anxiolytics during pregnancy without anxiety? *Op cit.* 46: 549-51 (2000).

Rathnapalan S, Diav-Citrin O, **Koren G:** Toward universal HIV testing in pregnancy. *Op cit.* 46: 508-10 (2000).

Diav-Citrin O, Okotore B, Lucarelli K, **Koren G:** Zopiclone use during pregnancy. *Op cit.* 46: 63-4 (2000).

**Koren G:** Caffeine during pregnancy? In moderation. *Op cit.* 46: 801-3 (2000).

Addis A, Dolovich LR, Einarson TR, **Koren G**: Can we use anxiolytics during pregnancy without anxiety? *Op cit.* 46: 549-51 (2000).

Rathnapalan S, Diav-Citrin O, King SM, **Koren G**: Universal HIV testing in pregnancy. *Op cit.* 46: 508-10, 519-22 (2000).

**Koren G**: Drugs in pregnancy; the nausea and vomiting paradigm. *Arch Pediatr* 2: 409-410, 2000.

Klinger G, **Koren G**: Antenatal phenobarbital for prevention of intraventricular hemorrhage in preterm infants. *Op cit.* 46: 1285-7 (2000).

Klinger G, **Koren G**: Controversies in antenatal corticosteroid treatment. *Op cit.* 46: 1571-3 (2000).

**Koren G**: Varicella virus vaccine before pregnancy. Important breakthrough in protecting fetuses. *Op cit.* 46: 1975-7 (2000).

Shuhaiber S, **Koren G**: Occupational exposure to inhaled anesthetic. Is it a concern for pregnant women. *Op cit.* 46: 2391-2 (2000).

Bailey B, Daneman R, Daneman N, Mayer JM, Leeder JS, **Koren G**: Discrepancy between CYP2D6 phenotype and genotype derived from postmortem-dextromethorphan blood level. *Forensic Sci Int.* 110: 61-70 (2000).

Klein J, Karaskov T, **Koren G**: Clinical applications of hair testing for drugs of abuse--the Canadian experience. *Op cit.* 107: 281-8 (2000).

Bailey B, Daneman R, Daneman N, Mayer JM, **Koren G**: Discrepancy between CYP2D6 phenotype and genotype derived from post-mortem dextromethorphan blood level. *Op cit.* 110: 61-70 (2000)

---

## "L"

**Lança AJ**, Adamson KL, Coen, KM, Chow BLC, Corrigan WA: The pedunculo-pontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: A correlative neuroanatomical and behavioral study. *Neuroscience* 96: 735-742 (2000).

**Lança AJ**, Sanelli TR, Corrigan WA: Nicotine-induced Fos-expression in the pedunculo-pontine mesencephalic tegmentum in the rat. *Neuropharmacology* 39: 2808-2817 (2000).

---

Herrmann N, **Lanctôt KL**, Myszak M: Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. *J Clin Psychopharmacol.* 20: 90-93 (2000).

**Lanctôt KL**, Herrmann N: Donepezil for behavioural disorders in dementia associated with Lewy bodies: a case series. *Int J Geriatr Psychiat.* 15:338-345 (2000).

Naranjo CA, Fourie J, Herrmann N, **Lanctôt KL**, Birt C, Yau KK: Probing peripheral and central cholinergic responses. *J Psychiatry Neurosci.* 25: 325-36 (2000).

**Lanctôt KL**, Bowles SK, Herrmann N, Best TS, Naranjo CA: Drugs mimicking dementia: Dementia symptoms associated with psychotropic drugs in institutionalized cognitively impaired patients. *CNS Drugs* 14: 381-90 (2000)

Paradiso-Hardy FL, Angelo CM, **Lanctôt KL**, Cohen EA: Hematologic dyscrasias associated with ticlopidine therapy: evidence of causality. *Can Med Assoc J.* 163: 1441-48 (2000).

**Lanctôt KL**: Issues in the pharmacotherapy of dementia. Invited commentary on "Pharmacologic Treatments of Dementia" by Davis, KL and Samuels SC. In: M. Maj, N. Sartorius (eds). *WPA Series Evidence and Experience in Psychiatry – Volume 3.* Chichester, John Wiley & Sons Ltd. pp. 259-261 (2000).

---

**Le AD**, Harding S, Shalev U, Juzytsch W, Shaham Y: The role of corticotropin releasing factor in stress-induced relapse to alcohol. *Psychopharmacology* 150: 317-324 (2000).

**Le AD**, Corrigan WA, Watchus J, Harding S, Juzytsch W, Li TK: Involvement of nicotinic receptors in alcohol self-administration. *Alcoholism: Clin Exp Res* 24: 155-163 (2000).

---

McLeman ER, Warsh JJ, Ang L, **Li PP**, Kalasinsky KS, Ross BM, Tong J, Schmunk G, Adams V, Kish SJ: The human nucleus accumbens is highly susceptible to G-protein downregulation by methamphetamine and heroin. *J Neurochem.* 74: 2120-2126 (2000).

Hua LV, Green M, Warsh JJ, **Li PP**: Lithium regulation of aldolase A expression in rat frontal cortex. *Biol Psychiatry* 48: 58-64 (2000).

Emamghoreishi M, **Li PP**, Schlichter L, Parikh SV, Cooke R, Warsh JJ: Associated disturbances in calcium homeostasis and G protein-mediated cAMP signaling in bipolar I disorder. *Biol Psychiatry* 48: 665-73 (2000).

Warsh JJ, Young LT, **Li PP**: Guanine nucleotide binding protein disturbances in bipolar disorder. In: Manji HK, Bowden CL, Belmaker RH, (eds.). *Bipolar Medications: Mechanisms of Action.* American Psychiatric Press, pp. 299-330 (2000).

**Li PP**, Andreopoulos S, Warsh JJ: Signal transduction in bipolar affective disorder. In: Reith MEA, (ed.). Cerebral Signal Transduction: From First to Fourth Messengers. Humana Press, pp. 283-309 (2000).

Warsh JJ, **Li PP**: Post-mortem studies in bipolar disorder. In: Soares JC, Gershon S, (eds.). Basic Mechanisms and Therapeutic Implications of Bipolar Disorder. Marcel Dekker, Inc., pp. 201-226 (2000).

---

## "M"

Xiong Z, O'Hanlon D, Becker LE, Roder JC, **MacDonald JF**, Marks A: Enhanced calcium transients in glial cells in neonatal cerebellar cultures derived from S100b null mice. *Experimental Cell Research* 257: 281-289 (2000).

Lei S, Jackson MF, Jia Z, Roder J, Bai D, Orser BA, **MacDonald JF**: Cyclic GMP-dependent feedback Inhibition of AMPA Receptors is Independent of PKG. *Nature Neuroscience* 3: 559-65. (2000).

Lu W-Y, Jackson MF, Bai D, Orser BA, **MacDonald JF**: In CA1 Pyramidal Neurons of the Hippocampus Protein Kinase C Regulates Calcium-dependent Inactivation of NMDA Receptors. *J Neuroscience* 20: 4452-61 (2000).

Taverna F, Xiong ZG, Roder JC, Salter MW, **MacDonald JF**: A single Lurcher mutation of the GluR1 Subunit of AMPA receptors. *J Biol Chem.* 275: 8475-9 (2000).

Sattler R, Xiong Z, Lu WY, **MacDonald JF**, Tymianski M: Distinct Roles of Synaptic and Extrasynaptic NMDA Receptors in Excitotoxicity. *J Neuroscience*, 20: 1 (2000).

---

**MacLeod SM**: Surviving the tsunami of drug therapy expenditures. *Can J Clin Pharmacol.* 7: 83-84 (2000).

---

Bamsey C, Mayeenuddin LH, Cheung R, **Mitchell J**: Dissociation of G-protein from rhabdomeric membranes decreases its interaction with rhodopsin and increases its degradation by calpain. *Comp Biochem Physiol. Part B* 127: 75-83 (2000).

---

Tavadia SMB, Mydlarski PR, Reis MD, **Mittmann N**, Pinkerton PH, Shear NH, Sauder DN: Screening for azathioprine toxicity-a pharmaco-economic study based on a target case. *J Am Acad Dermatology* 42: 628-632 (2000).

---

**Moore MJ**: Systemic therapy of bladder cancer. *Progress in Anti-Cancer Chemotherapy* 4:143-152 (2000).

Muzzamil T, **Moore MJ**, Ballinger JR: In vitro comparison of sestamibi, tetrofosmin, furifosmin as agents for functional imaging of multidrug resistance in tumors. *Cancer Biother Radiopharm.* 15: 339-346 (2000).

Warde P, Gospodarowicz MK, Panzarella T, Chow E, Murphy T, Catton CN, Sturgeon JF, **Moore M**, Milosevic M, Jewett MA: Long term outcome and cost in the management of stage I testicular seminoma. *Can J Urol.* 7: 967-972 (2000).

Rauschweiger D, Firby P, Hedley D, **Moore MJ**: Regulation of nucleoside transport function and its role in gemcitabine sensitivity. *Cancer Research* 60: 6075-9 (2000).

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, **Moore MJ**, Maroun JA, Ackland SP, Locker PK, Pirota N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. *New Engl J Med.* 343: 905-914 (2000).

Patnaik A, Warner E, Michael M, Egorin MJ, **Moore MJ**, Siu L, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza A: Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valsopodar in patients with advanced solid tumors. *J Clinical Oncology* 18: 3677-3689 (2000).

Miller WH Jr, Reyno LM, Loewen GR, Huan S, Winquist E, **Moore M**, Cato A 3rd, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E: A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. *Ann Oncol.* 11: 1387-9 (2000).

Ye L, Firby P, **Moore MJ**: Development and validation of an HPLC method for measurement of lovastatin in clinical trials of apoptosis modulation. *Ther Drug Monitoring* 22: 737-41 (2000).

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, **Moore MJ**, Bodrogi I, Albers P, Knuth A, Stockamp K, Kerbrat P, Sanchez Rovira P, Wersall, P, Cleall SP, Roychowdhury DF, Tomlin L, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus MVAC in advanced or metastatic bladder cancer: Results of a large randomized multinational multicenter, Phase III Study. *J Clin Oncol.* 18: 3068-77 (2000).

Dowling AJ, Czaykowski PM, Krahn MD, **Moore MJ**, Tannock IF: PSA responses to mitoxantrone and prednisone in patients with refractory prostate cancer – prognostic factors and generalizability of a multicentre trial to clinical practice. *J Urol.* 163: 1481-5 (2000).

---

## "N"

Hassan PC, Sproule BA, **Naranjo CA**, Herrmann N: Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. *J Clin Psychopharmacology* 20: 150-158 (2000).

**Naranjo CA**, Knoke DM, Bremner, KE: Variations in response to citalopram in alcohol dependent males and females. *J Psychiatry Neurosci.* 25: 269-275 (2000).

**Naranjo CA**, Fourie J, Herrmann N, Lanctot KL, Birt C, Yau KK: Probing peripheral and central cholinergic system responses. *J Psychiatry Neurosci.* 25: 325-336 (2000).

Lanctot KL, Bowles SK, Herrmann N, Best TS, **Naranjo CA**: Drugs mimicking dementia. Dementia symptoms associated with psychotropic drugs in institutionalized cognitively impaired patients. *CNS Drugs* 14: 381-390 (2000).

Turksen IB, Sproule BA, Kilic K, **Naranjo CA**: Fuzzy logic pharmacokinetic modeling. In: Adlassnig K-P, (ed.). *Proceedings of the ERUDIT-Workshop: Fuzzy Diagnostic and Therapeutic Decision Support.* Osterreichisch Computer Gesellschaft, Vienna, Austria, May 11-12, pp. 19-23 (2000).

**Naranjo CA**: Drug withdrawal syndromes. In: Gray J, (ed). *Therapeutic Choices*, 3rd Edition. Canadian Pharmacists Association, Ottawa, Canada, pp. 63-73 (2000).

---

**Neuman MG**, Malkiewicz IM, Shear NH: A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. *Clin Biochem.* 33: 517-524 (2000).

**Neuman MG**: Role of bile acids blocking ethanol-induced apoptosis. In: Leutchner U, (ed.). *Bile Acids and Liver Disease.* Kluwer Academic Publishing, London, UK, pp. 276-295 (2000).

---

Yeomans JS, Takeuchi J, Baptista M, Flynn DD, Lepik K, **Nobrega JN**, Fulton J, Ralph MR: Brain-stimulation reward thresholds raised by antisense oligonucleotide for the M5 muscarinic receptor infused near dopamine cells. *J Neurosci.* 20: 8861-8867 (2000).

D'Almeida V, Hipólido DC, Lobo LL, de Oliveira AC, **Nobrega JN**, Tufik S: Melatonin treatment does not prevent decreases in brain glutathione levels induced by sleep deprivation. *Europ J Pharmacol.* 390: 299-302 (2000).

---



## "O"

**O'Dowd BF**, Lee DK, Huang W, Nguyen T, Cheng R, Liu Y, Gershengorn MC, George SR: TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared to TRH-R1. *Molecular Endocrinology* 14:183-193 (2000).

Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam, Liu Y, Osmond D, George SR, **O'Dowd BF**: Characterization of Apelin, the ligand for the APJ receptor. *Journal of Neurochemistry*, 74: 34-41(2000).

Vandenbergh J, Thompson M, Comings D, Sellers E, Tyndale R, George SR, **O'Dowd BF**, Uhl G: Mutation analysis of the dopamine transporter (DAT1) gene: Three novel polymorphisms show no association with Tourette's syndrome or alcohol dependence. *Molecular Psychiatry*, 5:283-292 (2000).

Im DS, Heise CE, Harding MA, George SR, **O'Dowd BF**, Theodorescuc D, Lynch KR: Molecular cloning and characterization of a novel lysophosphatidic acid receptor, Edg-7, expressed in prostate. *Molecular Pharmacology*, 57:753-759 (2000).

Im DS, Heise CE, Ancellin N, **O'Dowd BF**, Shei G, Heavens RP, Rigby MR, Hla T, Mandala S, McAllister G, George SR, Lynch KR: Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. *Journal of Biological Chemistry*, 275:14281-14286 (2000).

Karasinska J, George SR, El-Ghundi M, Fletcher P, **O'Dowd B**. Modification of the D1 Receptor knockout phenotype in mice lacking both D1 and D3 dopamine receptors. *Eur. J. Pharmacol.*, 399:171-181 (2000).

Thompson M, Gonzales N, Nguyen T, Comings DE, George SR, **O'Dowd BF**. Serotonin transporter gene polymorphisms in alcohol dependence. *Alcohol*, 22: 61-67 (2000).

Lee SP, **O'Dowd BF**, Xie Z, Varghese G, George SR: Oligomerization of dopamine and serotonin receptors. *Neuropsychopharmacology*, 23:S32-S40 (2000).

Lee SP, **O'Dowd BF**, Ng GYK, Varghese G, Nguyen T, George SR: D2 dopamine receptors are antagonized by truncated receptor fragments and exist only as oligomers in the cell. *Molecular Pharmacology*, 58:120-128 (2000).

Tong Y, Chabot J-G, Shen S-H, **O'Dowd BF**, George SR, Quirion R: Ontogenic profile of the mu opioid receptor gene in the rat telecephalon and diencephalon: an in situ hybridization study. *J. Clinical Neurochemistry*, 18:209-222 (2000).

Lee DK, Lynch KR, Nguyen T, Im D-S, Cheng R, Saldivia V, Liu Y, Liu ISC, Heng HHQ, Seeman P, George SR, **O'Dowd BF**, Marchese A: Cloning and characterization of additional

members of the G protein-coupled receptor family. *Biochimica et Biophysica Acta* 1490:311-323 (2000).

Deng HB, Yu Y, Pak Y, **O'Dowd BF**, George SR, Surratt CK, Uhl G, Wang JB: Role for the C-terminus in agonist-induced mu opioid receptor phosphorylation and desensitization. *Biochemistry* 39:5492-5499 (2000).

Elmhurst JL, **O'Dowd BF**, Ng GYK, George SR: Alternatively spliced variant D3nf decreases the capacity of the D3 dopamine receptor to bind ligand. *Molecular Brain Research*, 80: 63-74 (2000).

George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, **O'Dowd BF**. Hetero-oligomerization of mu and delta opioid receptors: Generation of a novel pharmacology. *J. Biol. Chem*, 275: 26128-26135 (2000).

Heise CE, **O'Dowd BF**, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocca R, Bellefeuille JN, Abramowitz M, Cheng R, Williams DL, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 (CysLT2) receptor. *J. Biol. Chem.*, 275:30531-30536 (2000).

---

**Ogilvie RI**: Book review: *Cardiac Therapy* 5th edition MG Kahn. 1999 WB Saunders. *Can J Cardiol*.16: 1038 (2000).

**Ogilvie RI**: Commentary: Pulse pressure was positively associated with coronary risk and was superior to either systolic or diastolic blood pressure in predicting risk in older adults. *Evidence – Based Cardiovascular Medicine* 4: 14 (2000).

**Ogilvie RI**: Commentary: Can hypertensive therapy be discontinued? Can hypertension be cured? *Can J of CME* 8: 40-1 (2000).

**Ogilvie RI**: Intermittent Claudication. In: Gray J. (ed). *Therapeutic Choices* 3rd. edition. Canadian Pharmacists Association Ottawa. pp 281-4 (2000).

---

Iba MM, Fung J, Giannone JV, **Okey AB**: Comparative induction of CYP1A1 expression by pyridine and its metabolites. *Arch Biochem Biophys*. 378:299-310 (2000).

Pohjanvirta R, Simanainen U, Tuomisto J, **Okey AB**: Resveratrol, an aryl hydrocarbon receptor antagonist, does not prevent toxicity from 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats in vivo. *Organohalogen Compounds* 29:135-138 (2000).

Franc M-A, Pohjanvirta R, Tuomisto J, **Okey AB**: Regulation of expression of the aryl hydrocarbon receptor by TCDD in a dioxin-resistance model. *Organohalogen Compounds*. 29:139-142 (2000).

Harper PA, Wong JMY, Lam MSM, **Okey AB**: Sequence polymorphisms of the human aryl hydrocarbon receptor. *Organohalogen Compounds* 29:37-40 (2000).

---

## "P, Q"

Cong D, Doherty M, **Pang KS**: A new physiologically-based segregated flow model to explain route-intestinal metabolism. *Drug Metab Dispos*. 28: 224-235 (2000).

Doherty M, **Pang KS**: Route dependent metabolism of morphine in the vascularly perfused rat intestine preparation. *Pharm Res*. 17: 290-297 (2000).

Abu-Zahra TN, Wolkoff AW, Kim RB, **Pang KS**: Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. *Drug Metab Dispos*. 28: 801-806 (2000).

Abu-Zahra TN, **Pang KS**: Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. *Drug Metab Dispos*. 28: 807-813 (2000).

Schwab AJ, **Pang KS**: The multiple indicator dilution method and its utility in risk assessment. *Environ Health Perspect*. 5: 1-15 (2000).

---

## "R"

Lee C, **Riddick DS**: Transcriptional suppression of cytochrome P450 2C11 gene expression by 3-methylcholanthrene. *Biochem Pharmacol*. 59: 1417-1423 (2000).

**Riddick DS**: Toxicology in the new millennium: a report on the 32nd Annual STC Symposium. *STC News/Nouvelles* 19: 29-31 (2000).

Timsit YE, **Riddick DS**: Interference with growth hormone stimulation of hepatic cytochrome P450 2C11 expression in hypophysectomized male rats by 3-methylcholanthrene. *Toxicol Appl Pharmacol*. 163: 105-114 (2000).

---

Rashid M, **Roberts EA**: Non-alcoholic steatohepatitis in children. *J Pediatr Gastroenterol Nutr.* 30: 48-53 (2000).

Sokal E, **Roberts E**, Mieli-Vergani G, McPhillips P, Johnson M, Barber J, Dallow N, Boxall E, Kelly D: A Phase II, dose ranging study of the pharmacokinetics, safety and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. *Antimicrob Ag Chemother.* 44: 590-597 (2000).

Comanor L, Minor, J, Sokal EM, Conjeevaram HS, **Roberts EA**, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J: Statistical models for predicting response to interferon-a and spontaneous seroconversion in children with chronic hepatitis B. *J Viral Hepat.* 7: 144-152 (2000)

**Roberts EA**: Why treat chronic hepatitis B in childhood with interferon-a? *Gut* 46: 591-593. (2000).

Yeung LTF, **Roberts EA**: Hepatitis C. *Pediatric Web* ([www.PediatricWeb.com](http://www.PediatricWeb.com)) 4: (2000).

Wilson DC, Phillips MJ, Cox DW, **Roberts EA**: Severe hepatic Wilson disease in preschool children. *J Pediatr.* 137: 719-722 (2000).

**Roberts EA**, Harper PA, Li W, Yang S: Failure of Ah receptor to mediate induction of cytochromes P450 in the CYP1 family in the human hepatoma line SK-Hep-1. *Arch Biochem Biophys.* 384: 190-198 (2000).

**Roberts EA**: Drug-induced hepatotoxicity in children. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB, (eds.). *Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management*, 3rd edition. B.C. Decker, Hamilton pp. 1015-1032 (2000).

Cox DW, Tumer Z, **Roberts EA**: Copper-transport disorders: Wilson disease and Menkes disease. In: Fernandes J, Saudubray J-M, van den Berghe G, (eds.). *Inborn Metabolic Disease. Diagnosis and Treatment*, 3rd edition. Springer Verlag, Berlin, pp. 383-391 (2000).

---

## "S"

Frigeri C, Tsao J, Czerwinski W, **Schimmer BP**: Impaired steroidogenic factor 1 (NR5A1) activity in mutant Y1 mouse adrenocortical tumor cells. *Mol Endocrinol.* 14: 535-544 (2000).

Frigeri C, **Schimmer BP**: The activation function of steroidogenic factor-1 is impaired in ACTH-resistant Y1 mutants. *Endocr Res.* 26: 1005-1009 (2000).

Frigeri C, Tsao J, Qiu R, **Schimmer BP**: Roles for G protein  $\beta$  and  $g$  subunits and steroidogenic factor 1 (NR5A1) in expression of the ACTH receptor gene. In: Okamoto M, Ishimura Y,

Nawata H (ed.). Molecular steroidogenesis. Universal Academy Press, Inc., Tokyo pp. 249-252, (2000).

---

Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, **Seeman P**: A positron emission tomography study of quetiapine in schizophrenia - A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. *Arch Gen Psychiat*. 57: 553-559 (2000).

Kapur S, **Seeman P**: Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. *J Psychiat Neurosci*. 25: 161-166 (2000).

Silvestri S, Seeman MV, Negrete J-C, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, **Seeman P**: Increased dopamine D2 receptor binding following long-term treatment with antipsychotics in humans: A clinical PET study. *Psychopharmacology* 152: 174-180 (2000).

Lee DK, Lynch KR, Nguyen T, Im, D-S, Cheng R, Saldiva VR, Liu Y, Heng HHQ, **Seeman P**, George SR, O'Dowd BF, Marchese A: Cloning and characterization of additional members of the G protein-coupled receptor family. *Biochim Biophys Acta* 1490: 311-323 (2000).

**Seeman P**, Kapur S: Schizophrenia: More dopamine, more D2 receptors. *Proc Nat Acad Sci. U.S.A.* 97: 7673-7675 (2000).

Kapur S, Barsoum SC, **Seeman P**: Dopamine D2 blockade by haloperidol: 3H-raclopride reveals much higher occupancy than EEDQ. *Neuropsychopharmacology* 23: 595-598 (2000).

**Seeman P**, Nam D, Ulpian C, Liu ISC, Tallerico T: A new dopamine receptor, D2Longer, with a unique TG splice site, in human brain. *Molecular Brain Research* 76: 132-141 (2000).

Liu ISC, George SR, **Seeman P**: The dopamine D2Longer receptor has a high-affinity state and inhibits adenylate cyclase. *Op cit*. 77: 281-284 (2000).

Novak G, **Seeman P**, Tallerico T: Schizophrenia: elevated mRNA for calcium-calmodulin-dependent protein kinase IIb in frontal cortex. *Op cit*. 82: 95-100 (2000).

**Seeman P**: Antipsychotic drugs, dopamine receptors, and schizophrenia. In: Lidow MS (ed.). *Neurotransmitter receptors in actions of antipsychotic medications*. CRC Press LLC, Philadelphia, pp. 43-63 (2000).

**Seeman P**, Kapur S: Olanzapine binding to dopamine receptors in vitro and in vivo. In: Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G, (eds.). *Olanzapine (Zyprexa) - A Novel Antipsychotic*. Eli Lilly & Co., Lippincott Williams & Wilkins, Philadelphia, pp. 3-24 (2000).

**Seeman P**, Kapur S: The dopamine receptor basis of psychosis. In: Breier A, Tran PV, Herrera J, Bymaster F, Tollefson G, (eds.). Current issues in the Psychopharmacology of Schizophrenia. Eli Lilly & Co., Lippincott Williams & Wilkins, Philadelphia, (2000).

---

**Sellers EM**, Tyndale RF: Mimicking gene defects to treat drug dependence. *Ann NY Acad Sci.* 909: 233-246 (2000).

Kilicarslan T, **Sellers EM**: Lack of interaction of buprenorphine with flunitrazepam metabolism. *Am J Psychiatry* 157(: 1164-1166 (2000).

Miksys S, Rao Y, **Sellers EM**, Kwan M, Mendis D, Tyndale RF: Regional and cellular distribution of CYP2D subfamily members in rat brain. *Xenobiotica* 30: 547-564 (2000).

**Sellers EM**, Kaplan HL, Tyndale RF: Inhibiting cytochrome P450 2A6 increases oral nicotine bioavailability and decreases smoking. *Clin Pharmacol Ther.* 68: 35-43 (2000).

Vandenbergh DJ, Thompson M, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Comings D, **Sellers EM**, Tyndale RF, George SR, O'Dowd BF, Uhl GR: Human dopamine transporter gene: Coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. *Mol Psychiatry* 5: 283-292 (2000).

McLean W, Boucher A, Brennan M, Holbrook A, Orser R, Peachey J, **Sellers EM**: Is there an indication for the use of barbiturate-containing analgesics in the treatment of pain? Guidelines for their safe use and withdrawal management. *Can J Clin Pharmacol.* 7: 191-197 (2000).

Rao Y, Hoffmann E, Zia M, Zeman M, **Sellers EM**, Tyndale RF: Duplications and defects in the CYP2A6 gene: Identification, genotyping and in vivo effects on smoking. *Mol Pharmacol.* 58: 747-755 (2000).

Romach MK, Otton SV, Somer G, Tyndale RF, **Sellers EM**: Cytochrome P450 2D6 and treatment of codeine dependence. *J Clin Psychopharmacol.* 20: 43-45 (2000).

Busto UE, Bremner KE, Knight K, terBrugge K, **Sellers EM**: Long-term benzodiazepine therapy does not result in brain abnormalities. *Op cit.* 20: 2-6 (2000).

Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li N-Y, Säwe J, Tyndale RF, **Sellers EM**: Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. *Op cit.* 20: 435-444 (2000).

Baylon GJ, Kaplan HL, Somer G, Busto UE, **Sellers EM**: Comparative abuse liability of intravenous remifentanyl and fentanyl. *Op cit.* 20: 597-606 (2000).

Busto UE, Kaplan HL, Wright EC, Gomez-Mancilla B, Zawertailo L, Greenblatt DJ, **Sellers EM**: A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained release, bromazepam, and lorazepam. *Op cit.* 20: 628-635 (2000).

---

Bang KWA, Speck ER, Blanchette VS, Freedman J, **Semple JW**: Unique processing pathways within recipient antigen presenting cells determine IgG immune responsiveness against donor platelet MHC antigens. *Blood* 95: 1735-1742 (2000).

Ledent E, **Semple JW**, Berlin G: Flow cytometric analysis of white blood cell subsets in buffy coat derived platelet concentrates: the effect of pre and post storage filtration. *Vox Sang* 79: 235-241 (2000).

Leytin V, Moody M, **Semple JW**, Garvey MB, Freedman J: Flow cytometric parameters for characterizing platelet activation by measuring P-selectin (CD62) expression: Theoretical consideration and evaluation in thrombin-treated platelet populations. *Biochem Biophys Res Comm.* 269: 85-90 (2000).

Lazarus AH, Ellis J, **Semple JW**, Moody M, Crow AR, Freedman J: Comparison of platelet and immune parameters in patients with SLE and ITP. *Transfusion Sci.* 22: 19-27 (2000.).

Leytin V, Moody M, **Semple JW**, Garvey MB, Freedman J: Quantification of platelet activation status by analysing P-selectin expression. *Biochem Biophys Res Comm.* 273: 565-570 (2000.).

**Semple JW**: Total leukoreduction and platelet alloimmunization. In: Snyder EL, Blajchman MA, (eds.). *The Clinical and Molecular Basis of Transfusion-Induced Immunomodulation*. March 30-31, Yale University Press, New Haven, (2000).

**Semple JW**: Autoimmune pathogenesis. In: *The Compendium*. AABB Press, Bethesda MD., p. 33-39 (2000).

**Semple JW**, Speck ER, Bang A, Freedman J: Recipient mechanisms of platelet alloimmunization. In: Th C, Smit Sibinga, Das PC, The TH, (eds.). *The Molecular Biology of Blood Transfusion*. Kluwer Academic Publishers, Dordrecht, NL., p. 135-145 (2000).

---

Gupta AK, **Shear NH**: A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. *Drug Safety* 22: 33-52 (2000).

Gupta AK, DeKoven J, Lester RS, **Shear NH**, Sauder DN: Open-label study to evaluate the healing rate and safety of the Profore extra four-layer bandage system in patients with venous leg ulceration. *J Cut Med Surg.* 4: 13-15 (2000).



Eisen ER, Fish J, **Shear NH**: Management of drug-induced toxic epidermal necrolysis. *J Cut Med Surg.* 4: 96-102 (2000).

Tavadia SMB, Mydlarski PR, M.D. Reis MD, Mittmann N, Pinkerton PH, **Shear NH**, Sauder DN: Screening for azathioprine toxicity-a pharmacoeconomic study based on a target case. *J Am Acad Dermatol.* 42: 628-32 (2000).

Neuman MG, Malkiewicz I, **Shear NH**: A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. *Clin Biochem.* 33: 517-24 (2000).

Knowles SR, Uetrecht J, **Shear NH**: Idiosyncratic drug reactions: the reactive metabolite syndromes. *Lancet* 356: 1587-91 (2000).

---

## "T"

Davies PA, Hoffmann EB, Carlisle HJ, **Tyndale RF**, Hales TG: The influence of an endogenous 3 subunit on recombinant GABAA receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells. *Neuropharmacology* 39: 611-620 (2000).

Miksys S, Hoffmann E, **Tyndale RF**: Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. *Biochem Pharmacol.* 59: 1501-1511 (2000).

Vandenbergh DJ, Thompson M, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Comings D, Sellers EM, **Tyndale RF**, George SR, O'Dowd BF, Uhl GR: Human dopamine transporter gene: Coding region conservations among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. *Mol Psychiatry* 5: 283-292 (2000).

Miksys S, Rao Y, Sellers EM, Kwan M, Mendis D, **Tyndale RF**: Expression and distribution of CYP2D subfamily members in rat brain. *Xenobiotica* 30: 547-564 (2000).

Sellers EM, Kaplan HL, **Tyndale RF**: Inhibition of Cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. *Clin Pharmacol Ther.* 68: 35-43 (2000).

Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Kaplan H, Sellers EM, **Tyndale RF**: Duplications and Deletions in the CYP2A6 gene; Identification, Genotyping and In Vivo Effects on Smoking. *Mol Pharmacol.* 58: 747-755 (2000).

Sellers EM, **Tyndale RF**: Mimicking gene defects to treat drug dependence. *Ann NY Acad Sci.* 909: 233-46 (2000).

Mash DC, Kovera CA, Pablo J, **Tyndale RF**, Ervin FD, Williams IC, Singelton EG, Mayor M: Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. *Ann NY Acad Sci.* 914: 394-401 (2000).

Romach MK, Otton SV, Somer G, **Tyndale RF**, Sellers EM: Cytochrome P450 2D6 and treatment of codeine dependence. *J Clin Psychopharmacol.* 20: 43-5 (2000).

Kathiramalainathan K, Kaplan HL, Li N-Y, Romach MK, Busto UE, Säwe J, **Tyndale RF**, Sellers EM: Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. *J Clin Psychopharmacol.* 20: 435-444 (2000).

**Tyndale RF**, Sellers EM: Nicotine Metabolism Defect Reduces Smoking. In: Harris LS (ed.). *Problems of Drug Dependence 1999: Proceedings of the 61th Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc. US Department of Health and Human Services, Rockville.* 54-56 (2000).

---

## "U"

Guest I, **Uetrecht JP**: Drugs toxic to the bone marrow that target the stromal cells. *Immunopharmacology.* 46: 103-112 (2000).

Lai WG, Gardner I, Zahid N, **Uetrecht JP**: Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. *Drug Metab Disp.* 28: 255-263 (2000).

Liegeois,J, Zahid N, Bruhwylers J, **Uetrecht J**: Hypochlorous acid, a major oxidant produced by activated neutrophils, has low effect on two pyridobenzazepine derivatives, JL 3 and JL 13. *Archiv der Pharmazie* 333: 63-67 (2000).

Liu ZC, **Uetrecht JP**: Metabolism of ticlopidine by activated neutrophils: Implications for ticlopidine-induced agranulocytosis. *Drug Metab Disp.* 28: 726-730 (2000).

Williams DP, Pirmohamed M, Naisbitt DJ, **Uetrecht JP**, Park BK: Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. *Mol Pharmacol.* 58: 207-216 (2000).

**Uetrecht JP**: Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? *Curr Drug Metab.* 1: 133-141 (2000).

---

## "V"

Wong AH, Knapp MG, **Van Tol HH**: Dopamine receptor gene transfer into rat striatum using a recombinant adenoviral vector: rotational behaviour. *Neurosci Letters* 291:135-8 (2000).

Wong AH, Buckle CE, **Van Tol HH**: Polymorphisms in dopamine receptors: what do they tell us? *Eur J Pharmacol.* 410: 183-203 (2000).

Oak JN, Oldenhof J, **Van Tol HH**: The dopamine D(4) receptor: one decade of research. *Eur J Pharmacol.* 405: 303-27 (2000).

---

## "W, X, Y, Z"

Emamghoreishi M, Li PP, Schlichter L, Parikh SV, Cooke RG, **Warsh JJ**: Disturbances in Intracellular Calcium Homeostasis are Associated with Alterations in G protein Mediated cAMP Response in Bipolar I Disorder. *Biol Psychiatry* 48: 665-673 (2000).

McLeman E, **Warsh JJ**, Kish S: The Human Nucleus Accumbens is Highly Susceptible to G Protein Down-Regulation by Drugs of Abuse. *J Neurochem.* 74: 2120-2126 (2000).

Hua LV, Green M, **Warsh JJ**, Li P: Lithium regulation of aldolase A expression in rat frontal cortex: Identification by differential display. *Biol Psychiatry* 48: 58-64 (2000).

**Warsh JJ**, Li PP: Postmortem Studies in Bipolar Disorder. In: Soares JC, Gershon S, (eds.). *Basic Mechanisms and Therapeutic Implications of Bipolar Disorder*. New York, Marcel Dekker Inc., pp 201-226 (2000).

**Warsh JJ**, Young LT, Li PP: Guanine nucleotide binding protein disturbances in bipolar disorder. In: Manji HK, Bowden CL, Belmaker RH, (eds.). *Bipolar Medications: Mechanisms of Action*. American Psychiatric Press, pp. 299-330 (2000).

Li PP, Andreopoulos S, **Warsh JJ**: Signal Transduction in Bipolar Affective Disorder. In: Reith MEA (ed.). *Cerebral Signal Transduction: From First to Fourth Messengers*. Totawa, NJ: Humana Press Inc, pp 283-309 (2000).

---

Nicol CJ, Zielenski J, Tsui L-C, **Wells PG**: An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. *FASEB Journal* 14: 111-127 (2000).

---

**Woodland C**, Ito S, Granvil CP, Wainer IW, Klein J, Koren G: Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. *Life Sci.* 68: 109-117 (2000).